 |
 |
|
North East and North Cumbria
ICS Formulary |
| Formulary Chapter 5: Infections - Full Section
|
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
05.01 |
Antibacterial drugs (0,0)
|
|
|
Table 1. Summary of antibacterial therapy (0,0)
|
|
|
Table 2. Summary of antibacterial prophylaxis (0,0)
|
|
05.01.01 |
Penicillins (0,0)
|
|
05.01.01.01 |
Benzylpenicillin and phenoxymethylpenicillin
(4,0)
|
|
05.01.01.02 |
Penicillinase-resistant penicillins
(3,0)
|
|
05.01.01.03 |
Broad-spectrum penicillins
(3,0)
|
|
05.01.01.04 |
Antipseudomonal penicillins
(1,0)
|
|
05.01.01.05 |
Mecillinams
(1,0)
|
|
05.01.02 |
Cephalosporins, carbapenems and other beta-lactams (0,0)
|
|
|
Cephalosporins (0,0)
|
|
|
Other beta-lactam antibiotics (0,0)
|
|
05.01.02.01 |
Cephalosporins
(12,0)
|
|
05.01.02.02 |
Carbapenems
(4,0)
|
|
05.01.02.03 |
Other beta-lactam antibiotics
(2,0)
|
|
05.01.03 |
Tetracyclines
(4,0)
|
|
|
Tigecycline
(1,0)
|
|
05.01.04 |
Aminoglycosides
(6,0)
|
|
05.01.05 |
Macrolides
(6,0)
|
|
05.01.06 |
Clindamycin
(2,0)
|
|
05.01.07 |
Some other antibacterials
(3,0)
|
|
|
Chloramphenicol
(1,0)
|
|
|
Fosfomycin
(1,0)
|
|
|
Fusidic acid
(1,0)
|
|
|
Vancomycin and teicoplanin
(3,0)
|
|
|
Daptomycin
(1,0)
|
|
|
Linezolid
(3,0)
|
|
|
Quinupristin and dalfopristin (0,0)
|
|
|
Polymyxins
(1,0)
|
|
|
Rifaximin
(1,0)
|
|
|
Fidaxomicin
(1,0)
|
|
05.01.08 |
Sulphonamides and trimethoprim
(3,0)
|
|
05.01.09 |
Antituberculosis drugs
(14,0)
|
|
05.01.10 |
Antileprotic drugs
(2,0)
|
|
05.01.11 |
Metronidazole and tinidazole
(2,0)
|
|
05.01.12 |
Quinolones
(9,0)
|
|
05.01.13 |
Urinary-tract infections
(2,0)
|
|
05.02 |
Antifungal drugs (0,0)
|
|
|
Treatment of fungal infections (0,0)
|
|
|
Drugs used in fungal infections (0,0)
|
|
05.02.01 |
Triazole antifungals
(7,0)
|
|
05.02.02 |
Imidazole antifungals (0,0)
|
|
05.02.03 |
Polyene antifungals
(2,0)
|
|
05.02.04 |
Echinocandin antifungals
(3,0)
|
|
05.02.05 |
Other antifungals
(3,0)
|
|
05.03 |
Antiviral drugs (0,0)
|
|
05.03.01 |
HIV infection (0,0)
|
|
|
Nucleoside reverse transcriptase inhibitors
(8,0)
|
|
|
Protease inhibitors
(10,0)
|
|
|
Non-nucleoside reverse transcriptase inhibitors
(4,0)
|
|
|
Other antiretrovirals
(6,0)
|
|
|
Pharmacokinetic enhancers of anti-retrovirals
(1,0)
|
|
|
Combination Products
(14,0)
|
|
05.03.02 |
Herpesvirus infections (0,0)
|
|
05.03.02.01 |
Herpes simplex and varicella-zoster infection
(4,0)
|
|
05.03.02.02 |
Cytomegalovirus infection
(6,0)
|
|
05.03.03 |
Viral hepatitis (0,0)
|
|
05.03.03.01 |
Chronic hepatitis B
(4,0)
|
|
05.03.03.02 |
Chronic hepatitis C & hepatitis D
(10,0)
|
|
05.03.04 |
Influenza
(3,0)
|
|
05.03.05 |
Respiratory syncytial virus
(2,0)
|
|
05.03.06 |
COVID-19 therapeutics
(4,2)
|
|
05.04 |
Antiprotozoal drugs
(1,0)
|
|
05.04.01 |
Antimalarials (0,0)
|
|
|
Treatment of malaria
(2,0)
|
|
|
Falciparum malaria (treatment) (0,0)
|
|
|
Benign malarias (treatment) (0,0)
|
|
|
Prophylaxis against malaria (0,0)
|
|
|
Specific recommendations (0,0)
|
|
|
Artemether with lumefabtrine (0,0)
|
|
|
Chloroquine
(1,0)
|
|
|
Mefloquine
(1,0)
|
|
|
Primaquine
(1,0)
|
|
|
Proguanil (0,0)
|
|
|
Pyrimethamine
(1,0)
|
|
|
Quinine
(2,0)
|
|
|
Tetracyclines (0,0)
|
|
05.04.02 |
Amoebicides
(3,0)
|
|
05.04.03 |
Trichomonacides (0,0)
|
|
05.04.04 |
Antigiardial drugs
(2,0)
|
|
05.04.05 |
Leishmaniacides
(1,0)
|
|
05.04.06 |
Trypanocides (0,0)
|
|
05.04.07 |
Drugs for toxoplasmosis
(1,0)
|
|
05.04.08 |
Drugs for pneumocystis pneumonia
(4,0)
|
|
|
Treatment (0,0)
|
|
|
Prophylaxis (0,0)
|
|
05.05 |
Anthelmintics
(2,0)
|
|
05.05.01 |
Drugs for threadworms
(2,0)
|
|
05.05.02 |
Ascaricides (0,0)
|
|
05.05.03 |
Drugs for tapeworm infections (0,0)
|
|
|
Taenicides (0,0)
|
|
|
Hydatid disease (0,0)
|
|
05.05.04 |
Drugs for hookworms (0,0)
|
|
05.05.05 |
Schistosomicides
(1,0)
|
|
05.05.06 |
Filaricides (0,0)
|
|
05.05.07 |
Drugs for cutaneous larva migrans (0,0)
|
|
05.05.08 |
Drugs for strongyloidiasis (0,0)
|
|
|
|
